Product category:
Reagents and catalysts
News Release from: BD Biosciences | Subject: Oncomark
Edited by the Laboratorytalk Editorial
Team on 12 July 2002
Leukaemia classification gets tighter in
Leeds
The Haematological Malignancy Diagnostic Service based at Leeds General Infirmary has made significant improvements to its leukaemia diagnosis and classification service
The Haematological Malignancy Diagnostic Service based at Leeds General Infirmary has made significant improvements to its leukaemia diagnosis and classification service thanks to a new method using BD Oncomark reagents from BD Biosciences The Leeds department is an amalgamation of laboratories offering a centralised and highly specialised diagnostic service for leukaemias and lymphomas
This article was originally published on Laboratorytalk on 13 Nov 2002 at 8.00am (UK)
Related stories
Reagents speed up leukaemia diagnosis
"The reagents that are used to diagnose haematological malignancies have undergone vast improvements in the last couple of years"
Steve Richards, consultant clinical scientist in the department, explained: "BD Oncomark reagents are a range of high quality labelled monoclonal antibodies which, when used in specific combinations, allow us to diagnose the various types of leukaemia, look at the prevalence of normal cells, and even to identify different populations of leukaemic cells.
Our results are far better than before and the overall improvement in service has been particularly significant for our Acute Myeloid Leukaemia (AML) patients.
We can now get detailed information on AML patients in just two hours, information that is critical for deciding on the aggressive treatment programme that patient should undergo.".
• BD Biosciences: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
